SEARCH

SEARCH BY CITATION

References

  • 1
    Csendes, A, Smok, G, Cerda, G et al. Prevalence of Helicobacter pylori infection in 190 control subjects and 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's mucosa. Dis Esophagus 1997; 10, 38 42.
  • 2
    Liston, R, Pitt, MA, Banarjee, AK. Reflux oesophagitis and Helicobacter pylori infection in elderly patients. Postgrad Med J 1996; 72, 221 3.
  • 3
    Mihara, M, Haruma, K, Kamada, T et al. Low prevalence of Helicobacter pylori infection in patients with reflux esophagitis [abstract]. Gut 1996; 39 (Suppl. 2), A94(Abstract).
  • 4
    Hackelsberger, A, Schultze, V, Gunther, T et al. Helicobacter pylori prevalence in reflux esophagitis – a case control study [abstract]. Gastroenterology 1997; 112, A137(Abstract).
  • 5
    Holtmann, G, Cain, C, Malfertheiner, P et al. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with proton pump inhibitor Pantoprazole. Gastroenterology 1999; 117, 11 6.
  • 6
    O'connor, HJ. Review article: Helicobacter pylori and gastroesophageal reflux disease. Clinical implications and management. Aliment Pharmacol Ther 1999; 13, 117 27.
  • 7
    Schenk, BE, Kuipers, EJ, Klinkenberg-Knol, EC et al. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999; 94, 884 7.
    Direct Link:
  • 8
    O'connor, HJ & Cunnanek, K. Helicobacter pylori and gastro-oesophageal reflux disease. A prospective study. Ir J Med Sci 1994; 113, 369 73.
  • 9
    Borkent, MV & Beker, JA. Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine. Gut 1988; 29, 385 9.
  • 10
    Cheng, EH, Bermanski, P, Silversmith, M et al. Prevalence of Campylobacter pylori in esophagitis, gastritis and duodenal ulcer. Arch Inter Med 1989; 149, 1373 5.
  • 11
    Stewart, RJ, Boston, VE, Dodge, JA et al. Campylobacter pylori and reflux oesophagitis [letter]. Acta Paediatr Scand 1990; 79, 107.
  • 12
    Shallcross, TK, Wyatt, JI, Rathbone, BJ et al. Non-steroidal anti-inflammatory drugs, hiatus hernia and Helicobacter pylori in patients with oesophageal ulceration. Br J Rheumatol 1990; 29, 288 90.
  • 13
    Francoual, S, Lamy, P, Le Quintrec, Y et al. Helicobacter pylori: has it a part in the lesion of the gastroesophageal reflux? [Letter]. J Infect Dis 1990; 162, 1414.
  • 14
    Newton, NL, Bryan, R, Burnham, WR et al. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's mucosa. Gut 1997; 40, 9 13.
  • 15
    Lagergren, J, Bergström, R, Lindgren, A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340, 825 31.
  • 16
    Marshall, BJ. Epidemiology of H. pylori in Western countries. In: Hunt, RH & Tytgat, GNJ, eds. Helicobacter Pylori Basic Mechanisms to Clinical Cure. Dordrecht: Kluwer Academic Publishers, 1994: 75 84.
  • 17
    Hesketh, PJ, Clapp, RW, Doos, WG et al. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989; 64, 526 30.
  • 18
    El-Serag, HB & Sonnenberg, A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43, 327 33.
  • 19
    Vicari, JJ, Peek, RK, Falk, GW et al. The seroprevalence of CagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115, 50 7.
  • 20
    Chow, WFL, Blaser, MJ, Blot, WJ et al. An inverse correlation between CagA+ strains of Helicobacter pylori infection and risk of oesophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58, 588 90.
  • 21
    Grimley, CE, Loft, DE, Morris, AG et al. Virulent Helicobacter pylori in patients with gastric and oesophageal adeno- carcinoma. Gastroenterology 1997; 112, A571(Abstract).
  • 22
    Cave, DR & Vargas, M. Effect of Campylobacter protein on acid secretion by parietal cell. Lancet 1989; ii, 187 9.
  • 23
    Goggin, PM, Marrero, JK, Ahmed, H et al. Urea hydrolysis in Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1991; 3, 927 33.
  • 24
    Gutierrez, O, Melo, M, Segura, AM et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32, 664 8.
  • 25
    Di Mario, F, Del Bò, N, Buda, A et al. The prevalence of oesophagitis in patients with duodenal ulcer after eradication of Helicobacter pylori infection: one year follow up. Gastroenterology 1997; 112, A103.
  • 26
    McCallum, R & Walsh, JH. Relationship between lower esophageal sphincter pressure and serum gastrin concentra- tion in Zollinger–Ellison syndrome and other clinical settings. Gastroenterology 1979; 76, 78 81.
  • 27
    Levi, S, Beardshall, K, Haddad, G et al. Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet 1989; i, 1167 8.
  • 28
    Smith, JTL, Pounder, RE, Nwokolo, CV et al. Inappropriate hypergastrinemia in asymptomatic healthy subjects infected with Helicobacter pylori infection. Gut 1990; 31, 522 5.
  • 29
    McColl, KEL, Fullarton, GM, Chittajallu, RS et al. Plasma gastrin, daytime intragastric pH and nocturnal acid output before and at I and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol 1991; 26, 339 46.
  • 30
    El-Omar, E, Penman, IO, Ardill, JES et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109, 681 91.
  • 31
    Chittajallu, RS, Ardill, JES, McColl, KEL. The degree of hypergastrinemia induced by Helicobacter pylori is the same in duodenal ulcer patients and healthy volunteers. Eur J Gastroenterol Hepatol 1992; 4, 49 53.
  • 32
    El-Omar, E, Penman, IO, Dorrian, CA et al. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993; 34, 1060 5.
  • 33
    Harris, AW, Gummett, PA, Misiewicz, JJ et al. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Gut 1996; 38, 663 8.
  • 34
    Barnett, J, Beheler, EK, Appelman, HD et al. Campylobacter pylori is not associated with gastroparesis. Dig Dis Sci 1989; 34, 1677 80.
  • 35
    Pieramico, O, Ditshuneit, FL, Malfertheiner, P. Gastrointestinal motility in patients with non-ulcer dyspepsia: a role for Helicobacter pylori infection? Am J Gastroenterol 1993; 88, 364 8.
  • 36
    Tucci, A, Corinaldesi, R, Stanghellini, V et al. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 1992; 103, 768 74.
  • 37
    Fink, SM, De Barwick, KW, Luca, V et al. The association of histological gastritis with gastroesophageal reflux and delayed gastric emptying. J Clin Gastroenterol 1984; 6, 301 9.
  • 38
    Graham, DY & Yamaoka, Y. H. pylori and CagA: relationships with gastric cancer, duodenal ulcer and reflux esophagitis and its complications. Helicobacter 1998; 3, 145 51.
  • 39
    Genta, M, Huberman, RM, Graham, DY. The gastric cardia in Helicobacter pylori infection. Hum Pathol 1994; 25, 915 9.
  • 40
    Hackelsberger, A, Günther, T, Schultze, V et al. Prevalence and pattern of Helicobacter pylori gastritis in the gastric cardia. Am J Gastroenterol 1997; 92, 2220 4.
  • 41
    Mittall, RK, Halloway, RH, Penagini, R. Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109, 601 10.
  • 42
    Morgan, GP. Deleterious effects of prostaglandin E2 in reflux oesophagitis. Med Hypothesis 1996; 46, 42 4.
  • 43
    Wilson, KT, Ramanujam, KS, Mobley, HTL et al. Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. Gastro- enterology.; III 1524–33., 1996.
  • 44
    Schütze, K, Hentschel, E, Dragosics, B et al. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut 1995; 36, 831 3.
  • 45
    Labenz, J, Tillenberg, R, Peitz, V et al. Long-term consequences of Helicobacter pylori eradication: clinical aspects. Scand J Gastroenterol 1996; 31 (Suppl.215), 111 5.
  • 46
    Sacca, N, De Medici, A, Rodino, S et al. Reflux esophagitis: a complication of Helicobacter pylori (BP) eradication therapy [abstract]. Gut 1996; 39 (Suppl.3), A35(Abstract).
  • 47
    Labenz, J, Blum, AL, Bayerdörffer, E. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux oesophagitis. Gastroenterology 1997; 112, 1442 7.
  • 48
    Koike, T, Ohara, S, Sekine, H et al. Increase of gastric acid secretion after H. pylori eradication caused the development of reflux esophagitis [abstract]. Gastroenterology 1998; 114, A183(Abstract).
  • 49
    Tefera, S, Hatlebakk, JG, Berstad, A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999; 13, 915 20.
  • 50
    Carbone, F, Neri, M, Laterza, F et al. Twenty-four hour esophageal pHmetry in patients with non-ulcer dyspepsia is unchanged after H. pylori eradication [abstract]. Gastroenterology 1998; 114, G0342.
  • 51
    Vigneri, S, Termini, R, Di Mario, F et al. Omeprazole therapy modifies the gastric localization of Helicobacter pylori [letter]. Am J Gastroentero.1; 86: 1276−7., 1199.
  • 52
    Vigneri, S, Termini, R, Di Mario, F et al. The effects of omeprazole long-term treatment for duodenal ulcer on Helicobacter pylori [abstract]. Ir J Med Sci 1992; 161 (Suppl.10), A100(Abstract).
  • 53
    Vigneri, S, Termini, R, Scialabba, A et al. Omeprazole long-term treatment for duodenal ulcer effects on the gastric distribution of Helicobacter pylori [abstract]. Acta Gastroenterol Belg 1993; 56, A147(Abstract).
  • 54
    Vigneri, S, Termini, R, Scialabba, A et al. Helicobacter pylori and chronic gastritis during omeprazole long-term treatment for duodenal ulcer [abstract]. Gastroenterology 1994; 106 (2), A206(Abstract).
  • 55
    Kuipers, EJ, Vyterlinde, AK, Pena, AS et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345, 1525 8.
  • 56
    Logan, RPF, Walker, NW, Misiewicz, JJ et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36, 12 6.
  • 57
    Kuipers, EJ, Lundell, L, Klinkenberg-Knol, EC et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334, 1018 22.
  • 58
    Berstad, AE, Hatlebakk, JG, Maartman-Moe, H et al. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997; 4, 740 7.
  • 59
    Eissele, R, Brunner, G, Simon, B et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112, 707 17.
  • 60
    Stolte, M, Meining, A, Schmitz, JM et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12, 247 53.
  • 61
    Koop, R, Stumpf, K, Eissele, R et al. Antral Helicobacter pylori like organisms in different states of gastric acid secretion. Digestion 1991; 48, 230 6.
  • 62
    Solcia, E, Fiocca, R, Villani, L et al. Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. Scand J Gastroenterol 1996; 31 (Suppl.215), 105 10.
  • 63
    Kuipers, EJ, Lee, A, Klinkenberg-Knol, EC et al. Review article: the development of atrophic gastritis, Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther 1995; 9, 331 40.
  • 64
    Lundell, L, Mettinen, P, Myrvold, HE et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117, 319 26.
  • 65
    Lamberts, R, Creutzfeld, W, Strüber, HO et al. Long term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104, 1356 70.
  • 66
    Meining, A, Bossecker, K, Caspary, WF. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11, 729 34.
  • 67
    Sachs, G. Gastritis. Helicobacter pylori. & proton pump inhibitors. Gastroenterology 1997; 112, 1033 6.
  • 68
    Negrini, R, Savio, A, Poiesi, C et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996; 111, 655 65.
  • 69
    Azuma, T, Konishi, J, Tanaka, Y. Contribution of BLA-DQA gene to host's response against Helicobacter pylori. Lancet 1994; 343, 542 3.
  • 70
    Lee, A, Dixon, NE, Danon, SJ et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol 1995; 7, 461 5.
  • 71
    McGowan, CC, Cover, TL, Blaser, MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology 1996; 1 (926–3), 8.
  • 72
    Veldhuyzen Van Zanten, SIO, Dixon, MF, Lee, A. The gastric transitional zones: neglected links between gastroduodenal pathology and Helicobacter ecology. Gastroenterology 1999; 116, 1217 29.
  • 73
    Meyer-Rosberg, K, Scott, DR, Rex, D et al. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996; 111, 886 900.
  • 74
    Freston, JW. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspectives. Am J Gastroenterol 1997; 92 (Suppl.), 51S 7S.
  • 75
    Verdù, E, Armstrong, D, Fraser, R et al. Effect of H. pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36, 539 43.
  • 76
    Verdù, E, Armstrong, D, Idström, JP et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995; 37, 743 8.
  • 77
    Labenz, J, Tillenburg, B, Peitz, U et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110, 725 32.
  • 78
    Van Herwaarden, MA, Samson, M, Van Nispen, CHM. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13, 731 40.
  • 79
    Labenz, J, Tillenburg, B, Peitz, U et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 1997; 41, 33 6.
  • 80
    Gillen, D, Wizz, AA, Neithercut, WD. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44, 468 75.
  • 81
    Pantoflickova, D, Bereik, P, Blum, AL. Omeprazole: Helicobacter pylori makes thee greater yet. Gut 1999; 44, 448.
  • 82
    Riedel, T, Hartmann, K, Lühmann, R et al. The reversible H/K AT-P-ase antagonist By841 is more effective in elevating gastric pH in Helicobacter pylori positive than in Hp negative volunteers [Abstract]. Gastroenterology 1998; 1, 14:a268.
  • 83
    Verdù, E, Armstrong, D, Idström, JP et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31, 1151 6.
  • 84
    Klinkenberg-Knol, EC. Eleven years experience of continuous maintenance treatment with omeprazole in GERD patients [abstract]. Gastroenterology 1998; 114, A180(Abstract).
  • 85
    Peters, FTK, Kuipers, EJ, Garresh, S et al. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999; 13, 921 6.
  • 86
    Gillen, D, Wizz, AA, Ardill, JE et al. Rebound hypersecretion after omeprazole and its relation on treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116, 239 47.
  • 87
    Driman, DK, Wright, C, Tougas, G et al. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 1996; 41, 2039 47.
  • 88
    Howden, CW & Hunt, RH. Guidelines for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1998; 93, 2330 8.
    Direct Link:
  • 89
    Barrett, NR. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br J Surg 1950; 38, 175 82.
  • 90
    Hameeteman, W. Barrett's esophagus and adenocareinoma. In: F.Pace G Bianchi .Porro, ed. , Argomenti di patologia esofagea, Vol. 3 Springer Verlag Italia, Milano, 1998: 5 27.
  • 91
    Pera, M, Cameron, AJ, Trastek, VF et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104, 910 3.
  • 92
    Loffeld, RJLF, Ten Tije, BJ, Arends, JW. Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus. Am J Gastroenterol 1992; 87, 1598 600.
  • 93
    Sharma, VK, Demian, SE, Tailion, D et al. Examination of tissue distribution of Helicobacter pylori within columnar-lined esophagus. Dig Dis Sci 1999; 44, 1165 8.
  • 94
    Nandurkar, S & Talley, NJ. Barrett's esophagus: the long and short of it. Am J Gatroenterol: 1999; 94, 30 40.
    Direct Link:
  • 95
    Goldblum, JR, Vicari, JJ, Falk, GW et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 1998; 114, 633 9.
  • 96
    Quddus, MR, Henley, JD, Sulaiman, RA et al. Helicobacter infection and adenocarcinoma arising in Barrett's esophagus. Hum Pathol 1997; 28, 1007 9.
  • 97
    Wright, TA, Myskow, K, Kingsnorth, AN. Helicobacter pylori colonization of Barrett's esophagus and its progression to cancer. Dis Esophagus 1997; 10, 196 200.
  • 98
    El-Serag, BB, Sonnenberg, A, Jamal, MM et al. al. Corpus gastritis is protective against reflux oesophagitis. Gut 1999; 45, 181 5.
  • 99
    Richter, JE, Falk, GW, Vaezi, MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 1998; 93, 1800 2.
    Direct Link:
  • 100
    Blaser, MJ. Not all Helicobacter pylori strains are creted equal: should all be eliminated? Lancet 1997; 349, 1020 2.